We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




First Diagnostic Antibody Tests Now Available for Zika Virus

By LabMedica International staff writers
Posted on 15 Feb 2016
The complete package of two serological assays for Zika virus (ZIKV) infection enables diagnosis as well as population screening and surveillance by rapid, sensitive, and specific detection of antibodies (IgM, IgG) against the virus in blood of infected patients.

The test package, developed by EUROIMMUN AG (Luebeck, Germany), contains ELISA and indirect immunofluorescence (IIF) diagnostic tests and will shortly be used in studies at Fiocruz (Fundacao Oswaldo Cruz), an institute linked to the Brazilian health ministry. More...


“We have reacted immediately to the acute demand and developed ELISA and IIF tests which we have evaluated in cooperation with the Bernhard-Nocht Institute in Hamburg. The tests are suitable for the fast screening of large sample numbers and therefore enable monitoring of the virus spread,” said Katja Steinhagen, head of ELISA Infectious Serology, EUROIMMUN.

Serological tests are an important diagnostic supplement to direct detection, which is only effective during the viremic phase. Serological analyses are, moreover, crucial for epidemiological studies and monitoring. The EUROIMMUN test can detect both acute infections (in most cases from day-5 after onset of symptoms) and past infections. Test systems for direct detection of the virus (e.g., PCR) are useful only up to 5 days after onset of symptoms—after this, the virus itself is no longer detectable.

Zika fever is difficult to distinguish clinically from dengue fever and chikungunya fever, which manifest with similar symptoms and are endemic in much the same geographic regions. Thus, laboratory tests are crucial for effective differential diagnostics.

“Our ELISAs are based on very specific, recombinant antigens which are produced in our own research laboratories. Positive results are a clear indicator of a Zika virus infection” said Katja Steinhagen, “And our special immunofluorescence mosaics help laboratory physicians to investigate patient samples for other viral fever diseases in parallel. This is important for differential diagnosis, since in Latin America there are also dengue and chikungunya viruses, which cause similar symptoms and are transmitted by the same species of mosquitoes as the Zika virus. We hope our test systems can help to clarify as soon as possible whether there is a link between the cases of microcephaly and Zika infections.”

EUROIMMUN’S Anti-Zika Virus ELISA (IgM or IgG) tests provide automated detection using microplates coated with a recombinant protein from ZIKV. The highly specific antigen avoids cross-reactivity with other flaviviruses.

EUROIMMUN’S Anti-Zika Virus IIFT (IgM or IgG) utilize ZIKV-infected cells as the antigenic substrate. Positive and negative results are easily evaluated by microscopy. With the “Arboviral Fever Mosaic 2, the ZIKV substrate is incubated in parallel with substrates for Chikungunya virus and Dengue virus serotypes 1 to 4. This BIOCHIP combination enables secure interpretation of test results and differential diagnostic delimitation of ZIKV, Dengue virus, and Chikungunya virus infections.

Related Links:

EuroImmun 



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.